Cycurion Rejects Reverse Split, Ramps Up Fight Against Alleged Market Manipulation

summarizeSummary

Cycurion's CEO told shareholders the board will not pursue a reverse split, instead escalating a forensic probe into alleged market manipulation while touting a $28M revenue run rate and $58M contract.

check_boxKey Events · Corporate Governance and Compliance · CYCU

• Reverse Split Rejected

  The board and management declined a 7-for-1 reverse stock split, citing a need to protect shareholders and a prior experience where a split failed to provide durable price support.

• Market Manipulation Allegations

  Forensic findings detailed by the company include 89.9M shares traded in one session versus an 86.5M float, a 45% intraday drop on March 16, 2026 that triggered Rule 201, a surge in 'short exempt' sales during the restriction period, and spoofing patterns.

• Business Progress Highlighted

  The annual revenue run rate reached ~$28M, including $15.5M organic; the company also secured a $58M ten-year contract and built ~$8M in contracted backlog.

• Regulatory Engagement

  Cycurion is in contact with NASDAQ regarding the trading activity and intends to pursue legal and regulatory remedies against parties responsible for improper trading.

auto_awesomeAnalysis · CYCU · Technology

Management turned down a 7-for-1 reverse stock split, arguing it would hurt shareholders without addressing the root problems. Instead, the company is doubling down on a forensic investigation into what it describes as market manipulation—pointing to a session where over 100% of the float changed hands, a 45% intraday crash that triggered short-sale restrictions, subsequent circumvention via 'short exempt' trades, and spoofing patterns. The letter also spotlights business momentum: a $28M revenue run rate, a $58M ten-year contract, and $8M in backlog. For a micro-cap stock trading near its 52-week low and under a going-concern cloud, this is a high-stakes defense of both the share price and the Nasdaq listing.